On June 24, China National Intellectual Property Administration officially announced the list of winners of the 22nd China Patent Award. Qingfeng Pharma. new method for synthesizing lacosamide won the China Patent Excellence Award. This is another national honor of our company in terms of intellectual property in recent 2 years, following the "National Intellectual Property Demonstration Enterprise" and "National Intellectual Property Management System Certification".

Qingfeng pharmaceutical successfully developed lacosamide multi dosage forms and became the first enterprise in China to win the first imitation of tablets and injections at the same time. Lacosamide is the third generation of new antiepileptic drugs. Its new and unique mechanism of action brings more treatment options to patients with epilepsy. The company has entered the national medical insurance catalogue in 2019, greatly reducing the drug cost and benefiting more patients.

The China patent award is a national highest government department award that specifically rewards authorized patents and is recognized by the United Nations World Intellectual Property Organization (WIPO). The award has a high standard, which not only emphasizes the progressiveness of technology, but also its application, social value and enterprise management in the process of market transformation. This award is a high recognition of the company's product progressiveness, social value and R & D management level, which will have a more positive impact on the company's development.

The foundation will last forever and always climb the peak. Qingfeng pharmaceutical will continue to take "providing excellent services for human health" as its mission and strive to become a leading supplier of medical and health products in China.